Cigna · Pcsk 9 Sirna · US health-plan appeal rights

Pcsk 9 Sirna denied as experimental or investigational by Cigna?

Q: How long do I have to appeal a Cigna Pcsk 9 Sirna denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna coverage policy — PCSK9 Inhibitors / Express Scripts National PA

The Cigna angle on Pcsk 9 Sirna

## Why Cigna Denies a PCSK9 siRNA Agent as Experimental

Cigna issues experimental or investigational denials when its medical-review team determines that a treatment has not yet met the plan's definition of established clinical benefit — typically requiring FDA approval for the specific indication, inclusion in recognized medical compendia, and/or sufficient published evidence supporting safety and efficacy in the relevant patient population. For PCSK9 siRNA agents, this denial can occur if the plan's coverage policy has not yet been updated to reflect the current regulatory and evidence landscape, or if the specific indication on the claim falls outside the approved labeling.

Important first step: verify the current FDA approval status of the specific siRNA agent your prescriber ordered, for your specific indication, by reviewing the current prescribing label on FDA.gov or DailyMed. If the agent is FDA-approved for your indication, that is the central fact of your appeal.

## Why This Denial Is Appealable

Experimental denials are frequently reversed on appeal, particularly when the agent carries FDA approval for the indication at issue, or when it is listed in recognized compendia (such as those used by CMS and major plans). ACA §2719 and ERISA §503 require a full internal appeal and independent external review. External reviewers are required to consider current clinical evidence independently of the plan's own policy language. The external-review window is generally 4 months from the denial notice, with an expedited option.

## The Appeal Process and Timeline

1. Obtain Cigna's experimental/investigational criteria: request the specific coverage-policy section applied. Most policies define the criteria for meeting "established" status. 2. Confirm FDA approval status: obtain the current prescribing label. If your indication is on-label, this is your primary argument. 3. File Level 1 internal appeal with FDA label, any relevant compendia listings, and a prescriber letter, within the deadline on the denial notice. 4. Request external review if the internal appeal fails. External reviewers applying independent clinical standards often reach different conclusions than plan reviewers.

## Documentation to Gather

FDA-approved prescribing label: the current label for the specific siRNA agent, highlighting the approved indication that applies to your situation.
Compendia listings: if the agent appears in recognized drug compendia used by Cigna's policy (ask Cigna to specify which compendia it recognizes), obtain that listing.
Prescriber medical-necessity letter: explains why the agent is the appropriate treatment for your clinical situation, references the FDA-approved indication, and cites the relevant guideline organization (such as the ACC/AHA) generically.
Clinical records: diagnosis confirmation, relevant lab history, and prior-treatment history to establish the clinical context.
Cigna's coverage policy: the specific policy document applied to this denial, used to frame every element of the appeal.

## Criteria-Mapping Structure

Address each element of Cigna's experimental definition one by one: FDA approval status, compendia status, and evidence basis. For each, quote the policy criterion and then provide the specific evidence (label text, compendia entry, guideline organization citation) that satisfies it. If any element is genuinely unmet, your prescriber's letter should explain why the clinical evidence nonetheless supports coverage. This structured approach is the most effective format for reversing an experimental denial at both internal and external review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Pcsk 9 Sirna

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.